Core Scientific第四季度调整后每股亏损$(0.13) 超出$(0.08)预期,销售额为$94.92M 不及预期$99.92M

财报速递
27 Feb
Core Scientific(纳斯达克股票代码:CORZ)报告的季度每股亏损为$(0.13),比分析师一致预期的$(0.08)低62.5%。这比去年同期每股亏损$(0.51)增加了74.51%。公司报告的季度销售额为$94.92M,比分析师一致预期的$99.92M低5%。这比去年同期的$141.93M下降了33.12%。

以上内容来自Benzinga Earnings专栏,原文如下:

Core Scientific (NASDAQ:CORZ) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.08) by 62.5 percent. This is a 74.51 percent increase over losses of $(0.51) per share from the same period last year. The company reported quarterly sales of $94.92 million which missed the analyst consensus estimate of $99.92 million by 5.00 percent. This is a 33.12 percent decrease over sales of $141.93 million the same period last year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10